Nimotuzumab is a new humanized anti-EGFR MAb that binds to the extracellular domain of the EGFR with intermediate affinity and high specificity which results in the blockade of receptor-dependent signal transduction pathways and provides anti-tumor effects [12]. Here, EGFR is linked to neoplasm.